Rallybio (RLYB) Total Non-Current Liabilities (2020 - 2022)
Rallybio (RLYB) posted Total Non-Current Liabilities of $11.1 million for Q4 2022, down 5.16% sequentially from $11.7 million in Q3 2022, and up 69.71% YoY from $6.6 million in Q4 2021.
Rallybio (RLYB) Total Non-Current Liabilities (2020 - 2022) Analysis & Trends
Rallybio has reported Total Non-Current Liabilities for 3 years, with the latest figure at $11.1 million in Q4 2022.
- Quarterly Total Non-Current Liabilities rose 69.71% year-over-year to $11.1 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $11.1 million (up 69.71% YoY) and the FY2022 annual result came in at $11.1 million, up 69.71% from the prior year.
- Total Non-Current Liabilities declined to $11.1 million in Q4 2022 per RLYB's latest filing, from $11.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $11.7 million in Q3 2022 and troughed at $5.8 million in Q4 2020.
- A 3-year average of $8.0 million and a median of $7.4 million in 2021 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 69.71% in 2022, down 4.7% in 2022.
- Over 3 years, Total Non-Current Liabilities stood at $5.8 million in 2020, then climbed by 12.12% to $6.6 million in 2021, then surged by 69.71% to $11.1 million in 2022.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $11.1 million, $11.7 million, and $7.8 million for Q4 2022, Q3 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 11.12 Mn |
| Sep 30, 2022 | 11.72 Mn |
| Jun 30, 2022 | 7.76 Mn |
| Mar 31, 2022 | 6.32 Mn |
| Dec 31, 2021 | 6.55 Mn |
| Sep 30, 2021 | 7.34 Mn |
| Jun 30, 2021 | 7.41 Mn |
| Dec 31, 2020 | 5.84 Mn |